

# The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD

NCT05440422

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
<b>Enrollment</b>	45 participants

## Key Eligibility Criteria

---

### Inclusion (11)

- In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  - Provision of signed and dated informed consent form
  - Stated willingness to comply with all study procedures and availability for the duration of the study
  - Male or female, aged 18-80 years
  - In good general health as evidenced by medical history or diagnosed with SLE diagnosed per American College of Rheumatology 1997 revised SLE classification criteria.
- ... and 6 more (see full listing online)

### Exclusion (54)

- An individual who meets any of the following criteria will be excluded from participation in this study:
  - Any condition that, in the opinion of the Investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results.
  - Concurrent enrolment in another clinical study with an investigational product
  - Major surgery within 8 weeks before signing the ICF or elective major surgery planned during the study period.
- ... and 49 more (see full listing online)

## Locations (1 total)

---

National Institutes of Health Clinical Center, Bethesda, Maryland, United States